Bi-specific Probody targeting EGFR - Amgen/CytomX Therapeutics

Drug Profile

Bi-specific Probody targeting EGFR - Amgen/CytomX Therapeutics

Alternative Names: EGFRxCD3 bispecific monoclonal antibody - Amgen/CytomX; EGFRxCD3 bispecific Probody - Amgen/CytomX

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen; CytomX Therapeutics
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 26 Oct 2017 Pharmacodynamics, adverse events and pharmacokinetics data from preclinical studies in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 03 Oct 2017 Amgen and CytomX Therapeutics enter into an agreement to co-develop a Bispecific Probody targeting EGFR for cancer
  • 03 Oct 2017 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top